Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies ; volume:7 ; number:1 ; day:24 ; month:11 ; year:2012 ; pages:1-11 ; date:12.2012
Orphanet journal of rare diseases ; 7, Heft 1 (24.11.2012), 1-11, 12.2012
- Urheber
-
Germain, Dominique P.
- Beteiligte Personen und Organisationen
-
Giugliani, Roberto
Hughes, Derralynn A.
Mehta, Atul
Nicholls, Kathy
Barisoni, Laura
Jennette, Charles J.
Bragat, Alexander
Castelli, Jeff
Sitaraman, Sheela
Lockhart, David J.
Boudes, Pol F.
SpringerLink (Online service)
- DOI
-
10.1186/1750-1172-7-91
- URN
-
urn:nbn:de:1111-2016050120465
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Germain, Dominique P.
- Giugliani, Roberto
- Hughes, Derralynn A.
- Mehta, Atul
- Nicholls, Kathy
- Barisoni, Laura
- Jennette, Charles J.
- Bragat, Alexander
- Castelli, Jeff
- Sitaraman, Sheela
- Lockhart, David J.
- Boudes, Pol F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease
![Hydrophob immobilisierte β-Galactosidase [Beta-Galactosidase]](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Hydrophob immobilisierte β-Galactosidase [Beta-Galactosidase]
Characterisation of novel α-galactosidase [alpha-galactosidase] A mutations in Fabry disease based on in vitro, in vivo and pharmacological data
Lysosomale β-Galactosidase [Beta-Galactosidase] der Rattenleber
Fabry-Münster-Studie (FaMüS) : Diskussion des Fabryzentrum-Münster-Kollektivs und der kardiologischen Effektivität der α-Galactosidase-Ersatz-Therapie [Alpha-Galactosidase-Ersatz-Therapie]
Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease
Untersuchungen zur Transkriptionsregulation der humanen lysosomalen β-Galactosidase [Beta-Galactosidase]
Stratification of Fabry mutations in clinical practice: a closer look at α‐galactosidase A‐3D structure
Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice
Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease
Hydrophob immobilisierte β-Galactosidase [Beta-Galactosidase]
Characterisation of novel α-galactosidase [alpha-galactosidase] A mutations in Fabry disease based on in vitro, in vivo and pharmacological data
Lysosomale β-Galactosidase [Beta-Galactosidase] der Rattenleber
Fabry-Münster-Studie (FaMüS) : Diskussion des Fabryzentrum-Münster-Kollektivs und der kardiologischen Effektivität der α-Galactosidase-Ersatz-Therapie [Alpha-Galactosidase-Ersatz-Therapie]
Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease
Untersuchungen zur Transkriptionsregulation der humanen lysosomalen β-Galactosidase [Beta-Galactosidase]
Stratification of Fabry mutations in clinical practice: a closer look at α‐galactosidase A‐3D structure
Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice
Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease
Hydrophob immobilisierte β-Galactosidase [Beta-Galactosidase]
Characterisation of novel α-galactosidase [alpha-galactosidase] A mutations in Fabry disease based on in vitro, in vivo and pharmacological data
Lysosomale β-Galactosidase [Beta-Galactosidase] der Rattenleber
Fabry-Münster-Studie (FaMüS) : Diskussion des Fabryzentrum-Münster-Kollektivs und der kardiologischen Effektivität der α-Galactosidase-Ersatz-Therapie [Alpha-Galactosidase-Ersatz-Therapie]
Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease
Untersuchungen zur Transkriptionsregulation der humanen lysosomalen β-Galactosidase [Beta-Galactosidase]
Stratification of Fabry mutations in clinical practice: a closer look at α‐galactosidase A‐3D structure
Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice